Transforming Diabetes Care

AT278, a novel formulation of insulin with an ultra-rapid glucose lowering action, can transform diabetes care by enabling the development of a fully closed loop artificial pancreas (AP) system.

The AT278 formulation was developed using Arecor's proprietary formulation technology and is based on a unique mixture of two ingredients. The first results in significant acceleration of insulin absorption from the injection site and the second ensures excellent stability of insulin in the pump.

The ultra-rapid action of AT278 has already been demonstrated in a Phase I clinical trial where the onset and offset of exposure was superior to that Novorapid.

The objective of the proposed Phase Ib trial is to compare the pharmacokinetic and pharmacodynamic time action profile
of AT278 with Novorapid and Humulin R U500 when administered to patients with Type II diabetes. This is a critical step forward in understanding ultra-rapid-acting insulins and the translation of these products to automated insulin delivery systems.

It has been shown that TIR is significantly improved when patients are using an automated insulin delivery system (AP), where BG is continuously measured, an algorithm calculates insulin requirements based on real-time BG which is then automatically delivered by a pump.

Current best-in-class insulins are not fast enough acting to control BG within an AP system around meal-times (when BG rises rapidly) and the patient must manually intervene (hybrid closed loop, HCL).

The challenge is to develop an ultra-rapid acting insulin that enables a fully closed loop AP system. This will be transformative for T1D and T2D patients, improving quality of life and health outcomes. In addition, a true AP system will ultimately greatly reduce the wider burden on health care systems globally.